Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]
<p>Abstract</p> <p>Background</p> <p>Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high incidence of coronary heart disease (CHD) and stroke, b...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMC
2001-07-01
|
| סדרה: | Current Controlled Trials in Cardiovascular Medicine |
| נושאים: | |
| גישה מקוונת: | http://cvm.controlled-trials.com/content/2/4/195 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|